MARKET

LJPC

LJPC

La Jolla Pharmaceutical Co
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.060
0.000
0.00%
After Hours: 4.060 0 0.00% 16:00 05/19 EDT
OPEN
4.070
PREV CLOSE
4.060
HIGH
4.150
LOW
4.010
VOLUME
30.52K
TURNOVER
0
52 WEEK HIGH
5.69
52 WEEK LOW
3.400
MARKET CAP
104.02M
P/E (TTM)
7.26
1D
5D
1M
3M
1Y
5Y
Recap: La Jolla Pharmaceutical Q1 Earnings
La Jolla Pharmaceutical (NASDAQ:LJPC) reported its Q1 earnings results on Monday, May 16, 2022 at 04:15 PM. Here's what investors need to know about the announcement.
Benzinga · 3d ago
La Jolla Pharmaceutical GAAP EPS of $0.00 misses by $0.01, revenue of $10.43M misses by $2.67M
La Jolla Pharmaceutical press release (NASDAQ:LJPC): Q1 GAAP EPS of $0.00 misses by $0.01. Revenue of $10.43M (-69.4% Y/Y) misses by $2.67M. “We are pleased to report that La Jolla
Seekingalpha · 3d ago
La Jolla Pharmaceutical's Earnings Decline in March Quarter, Sales Increase
MT Newswires · 3d ago
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3d ago
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 21:35
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:35
The past five years for La Jolla Pharmaceutical (NASDAQ:LJPC) investors has not been profitable
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
Simply Wall St. · 04/28 15:28
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most like...
Benzinga · 03/21 14:44
More
No Data
Learn about the latest financial forecast of LJPC. Analyze the recent business situations of La Jolla Pharmaceutical Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LJPC stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
High4.000
Average4.000
Low4.000
Current 4.060
EPS
Actual
Estimate
-0.09-0.030.030.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 105
Institutional Holdings: 26.54M
% Owned: 103.59%
Shares Outstanding: 25.62M
TypeInstitutionsShares
Increased
14
873.66K
New
5
24.06K
Decreased
16
689.16K
Sold Out
15
1.25M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman/Director
Kevin Tang
President/Chief Executive Officer/Director
Larry Edwards
Chief Financial Officer
Michael Hearne
Other
Tony Hodges
Independent Director
Laura Douglass
Independent Director
Craig Johnson
Independent Director
David Ramsay
Independent Director
Robert Rosen
No Data
No Data
About LJPC
La Jolla Pharmaceutical Company is engaged in development and commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline include GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA (angiotensin II) injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. Its XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. The Company's early-stage clinical development product candidate include TP-6076, TP-271, and TP-2846. Its TP-6076 is a IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia.

Webull offers kinds of La Jolla Pharmaceutical Company stock information, including NASDAQ:LJPC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LJPC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LJPC stock methods without spending real money on the virtual paper trading platform.